Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. BioMarin Pharmaceutical beat analysts’ revenue expectations by ...

Before you invest in BioMarin Pharmaceutical Inc. (BMRN), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.

In the last three months, 8 analysts have published ratings on Biomarin Pharmaceutical BMRN, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a ...

BioMarin’s Q4 adjusted EPS rose to $0.92, surpassing the $0.53 consensus. 2025 sales guidance set at $3.1 billion-$3.2 billion, with EPS expected at $4.20-$4.40. Join Nic Chahine live on ...

Shares of BioMarin Pharmaceutical (BMRN ... Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...